Structural bone changes in spondyloarthritis: Mechanisms, clinical impact and therapeutic considerations

American Journal of the Medical Sciences

Volumn 341, Issue 4, 2011, Pages 269-271

  Schett, Georg ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Bone formation; Bone remodeling; Spondyloarthritis; Structural damage; Syndesmophytes

Indexed keywords

BONE STRUCTURE; CONFERENCE PAPER; DISEASE ASSOCIATION; HUMAN; INFLAMMATORY DISEASE; OSTEITIS; PATHOPHYSIOLOGY; SPONDYLARTHRITIS;

EID: 79953205984     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31820f8b29     Document Type: Conference Paper

References (15)

1. Wanders A, Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756-65. (Pubitemid 40852884)
2. van der Heijde D, Landewe R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063-70.
3. van der Heijde D, Landewe R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-31. (Pubitemid 351705922)
4. van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009;11:R127.
5. Schett G, Saag KG, Bijlsma JW. From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis 2010;69:1415-9.
6. Appel H, Kuhne M, Spiekermann S, et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006;54:2845-51. (Pubitemid 44497763)
7. Neidhart M, Baraliakos X, Seemayer C, et al. Expression of cathepsin K and matrix metalloproteinase 1 indicate persistent osteodestructive activity in longstanding ankylosing spondylitis. Ann Rheum Dis 2009;68:1334-9.
8. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005;115:1571-9. (Pubitemid 40814665)
9. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63.
10. Uderhardt S, Diarra D, Katzenbeisser J, et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis 2010;69: 592-7.
11. Heiland GR, Zwerina K, Baum W, et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis 2010;69:2152-9.
12. Appel H, Ruiz-Heiland G, Listing J, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009;60:3257-62.
13. Appel H, Rudwaleit M, Sieper J. Relevance of osteoproliferation as an outcome parameter in ankylosing spondylitis. Nat Clin Pract Rheumatol 2008;4:578-9.
14. Lories RJ, Derese I, Luyten FP. Inhibition of osteoclasts does not prevent joint ankylosis in a mouse model of spondyloarthritis. Rheumatology (Oxford) 2008;47:605-8. (Pubitemid 351619197)
15. Schett G, Stolina M, Dwyer D, et al. Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. Arthritis Rheum 2009;60:2644-54.